Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza Combination ...

Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible. In October, the FDA issued the clinical hold due to a spontaneous ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.

Are you preparing for a job interview and wondering what the hiring manager will ask you? One common question is, “What are your career goals?” This can be a difficult question to answer, especially ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined Covid-flu vaccine and standalone flu inoculation due to safety concerns.

Novavax's planned phase 3 clinical trials just hit a roadblock. The stock didn't look that attractive before this development. This setback adds more uncertainty to Novavax's prospects. However ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...